

190. The fatty acid-anticancer compound conjugate composition of claim 1, wherein the amount in the container is at least about 400% greater than the MTD for the unconjugated at least one anticancer compound.

191. The fatty acid-anticancer compound conjugate composition of claim 1, wherein the fatty acid is a C8-C26 unbranched, naturally occurring fatty acid.

192. The method of claim 17, wherein the amount of the fatty acid-anticancer compound conjugate composition administered is at least about 200% greater than the MTD for the unconjugated at least one anticancer compound.

193. The method of claim 17, wherein the amount of the fatty acid-anticancer compound conjugate composition administered is at least about 300% greater than the MTD for the unconjugated at least one anticancer compound.

194. The method of claim 17, wherein the amount of the fatty acid-anticancer compound conjugate composition administered is at least about 400% greater than the MTD for the unconjugated at least one anticancer compound.

195. The method of claim 17, wherein the fatty acid is a C8-C26 unbranched, naturally occurring fatty acid.

196. The kit of claim 33, wherein the amount of the at least one fatty acid-anticancer compound conjugate is at least about 50% greater than the MTD for the unconjugated at least one anticancer compound.

197. The kit of claim 33, wherein the amount of the at least one fatty acid-anticancer compound conjugate is at least about 100% greater than the MTD for the unconjugated at least one anticancer compound.